Takeda Pharmaceutical Co Ltd
TAK
Company Profile
Business description
Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company’s five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
Contact
1-1, Nihonbashi-Honcho 2-Chome
Chuo-ku
Tokyo103-8668
JPNT: +81 332782306
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
47,455
Stocks News & Analysis
stocks
A collection of our best stock opportunities
Our latest articles about where we see opportunities in the market.
stocks
Morningstar analyst reacts to Macquarie Group’s earnings
Banking Analyst Nathan Zaia’s analysis of MQG’s results.
stocks
Undervalued ASX share showing progress in global efforts
More clarity on the path forward in the UK.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,966.70 | 3.20 | 0.04% |
| CAC 40 | 7,882.14 | 81.26 | 1.04% |
| DAX 40 | 24,200.18 | 229.82 | 0.96% |
| Dow JONES (US) | 44,837.56 | 64.36 | -0.14% |
| FTSE 100 | 9,104.55 | 23.11 | 0.25% |
| HKSE | 25,524.45 | 37.68 | -0.15% |
| NASDAQ | 21,178.58 | 70.27 | 0.33% |
| Nikkei 225 | 40,674.55 | 323.72 | -0.79% |
| NZX 50 Index | 12,936.41 | 25.67 | 0.20% |
| S&P 500 | 6,389.77 | 1.13 | 0.02% |
| S&P/ASX 200 | 8,704.60 | 6.90 | 0.08% |
| SSE Composite Index | 3,609.71 | 11.77 | 0.33% |